CVD and Renal Disease in T2DM: Pivotal Role of PAs in Patient Management

This live meeting took place on May 21, 2018. 
An on-demand webcourse of the live meeting content will be available in August 2018.

A CME-certified Symposium

Date: Monday, May 21, 2018
Time: 5:00 – 7:00 PM

Hilton New Orleans Riverside
Two Poydras Street
New Orleans, LA 70130
St. James Ballroom, Level 3

5:00 – 5:30 PM: Registration
5:30 – 7:00 PM: CME Program

Welcome, Introductions, and Pre-survey
Individualizing Antihyperglycemic Therapy: Guideline Recommendations
Identification and Management of Cardiovascular and Renal Comorbidities in T2DM
Q&A Session, Post-activity Survey, and Concluding Remarks

Vivian Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Scott Urquhart, PA-C, DFAAPA
Chair, Metabolic and Endocrine Disease Summit (MEDS) 
Adjunct Clinical Professor, James Madison University PA Program
Clinical Instructor, George Washington University PA Program
Past President, American Society of Endocrine PAs (ASEPA)
Diabetes and Thyroid Associates
Fredericksburg, VA

CME Course Director
Elliot Sternthal, MD, FACP, FACR

Clinical Director of Endocrinology
VA Boston Healthcare System
Assistant Professor of Medicine
Boston University School of Medicine

Type 2 diabetes mellitus (T2DM) continues to pose a major public-health problem. According to the most recent National Committee for Quality Assurance (NCQA) data, approximately 63% of patients with diabetes are not at HbA1c goal (<7.0%). Management is complicated by comorbidities, such as cardiovascular disease (CVD) and renal complications. CVD not only remains the leading cause of death in patients with T2DM, the presence of cardiovascular complications reduces patient quality of life. In addition, chronic kidney disease, which is often underdiagnosed until later stages of the disease, increases the risk of CVD in patients with T2DM. Reduction of CVD through lifestyle intervention and pharmacologic therapy in patients with T2DM is critical.

Because of the shortage of primary care physicians, PAs play a pivotal role in managing patients with T2DM and controlling morbidity and mortality, i.e. recognizing and initiating corrective measures for inadequate treatment regimens, helping patients set and achieve therapeutic goals, and assessing diabetes-related complications. According to a recent survey, these clinicians see as many as 30 patients with T2DM every week, emphasizing the need for effective diabetes education.

The primary intended audience for this educational activity is PAs.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Provide individualized pharmacologic therapy for T2DM management using guideline recommendations and patient presentations

  • Identify the cardiovascular and renal benefits of newer antihyperglycemic agents in patients with T2DM and associated comorbidities

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

This program has been reviewed and is approved for a maximum of 1.50 AAPA Category 1 CME credits by the PA Review Panel. PAs should claim only those hours actually spent participating in the CME activity.

This program was planned in accordance with AAPA’s CME Standards for Live Programs and for Commercial Support of Live Programs.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided onsite.

There is no fee associated with this program.

Event staff will be glad to assist you with any special needs. Please email at least 5 days prior to the program.

Jointly provided by Boston University School of Medicine and Rockpointe


This activity is supported by an independent educational grant from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. 

This symposium is neither supported, sponsored, nor endorsed by AAPA.